Prolactinoma
📧 Sign up to get email alerts when something new happens for Prolactinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
This clinical trial update notes that the NICHD study on pituitary tumors and related hypothalamic disorders is actively recruiting, coverin…
-
FDA approval · 2026-03-18FDA Approved: CABERGOLINE — Supplemental Application (SOLA Pharmaceuticals, LLC)
FDA approves a supplemental application for Cabergoline from SOLA Pharmaceuticals, LLC, enabling continued use under the approved indication…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Safety and Potency of a High Cabergoline Dosage in Microprolactinomas [Phase 3]
A Phase 3 clinical trial is evaluating the safety and efficacy of a high-dose cabergoline regimen in people with microprolactinomas. The stu…
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: A Study of Pasireotide in People With Prolactinoma [Phase 2]
A Phase 2 clinical trial evaluating pasireotide for prolactinoma (prolactin-producing pituitary tumor) is currently recruiting.
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: How Estrogen Fluctuations Before Diagnosis Affect the Size Prolactin-secreting Tumors
This clinical trial investigates whether estrogen fluctuations before diagnosis influence the size of prolactin-secreting pituitary tumors (…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-01-08Clinical Trial Update: The PROMISE Survey
The PROMISE Survey trial update provides status information on a University Hospital Basel study; it targets prolactinoma and pituitary aden…
-
CLINICAL_TRIALS research · 2025-12-05Clinical Trial Update: Validation of a Quality of Life Metric "Prolac-10"
The study validating the Prolac-10 quality-of-life metric for prolactin-producing pituitary tumors has been terminated.
-
CLINICAL_TRIALS research · 2025-09-23Clinical Trial Update: Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment [Phase 4]
Phase 4 clinical trial examining metabolic outcomes in prolactinoma patients on dopamine agonist therapy. Recruitment is ongoing.
-
CLINICAL_TRIALS research · 2024-08-15Clinical Trial Update: Surgical and Pharmacological Efficacy of Knosp Grade 0-2 Prolactinoma [NA]
This clinical trial update investigates surgical and pharmacological approaches for Knosp Grade 0-2 prolactinomas. The study status is NOT_Y…
-
CLINICAL_TRIALS trial_result · 2024-05-24Clinical Trial Update: Exercise Capacity and Physical Activity Level in Prolactinoma Patients
A completed clinical trial update examining exercise capacity and physical activity levels in patients with prolactinoma. The study status i…
-
FDA approval · 2022-04-27FDA Approved: BROMOCRIPTINE MESYLATE — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
FDA approved a supplemental application for bromocriptine mesylate submitted by Zydus Pharmaceuticals USA Inc.
-
CLINICAL_TRIALS trial_result · 2021-07-30Clinical Trial Update: Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluated ropinirole, a non-ergoline dopamine agonist, for hyperprolactinemia and prolactinoma. The study is comp…
-
CLINICAL_TRIALS trial_result · 2020-07-20Clinical Trial Update: PRolaCT - Three Prolactinoma RCTs [Phase 4]
Phase 4 clinical trial update for three prolactinoma trials (PRolaCT) sponsored by Leiden University Medical Center.
-
FDA approval · 2018-08-01FDA Approved: CABERGOLINE — Original Application (Ingenus Pharmaceuticals, LLC)
FDA approved Cabergoline (original application) from Ingenus Pharmaceuticals, LLC, expanding access to this dopamine agonist under an ANDA. …
-
CLINICAL_TRIALS other · 2017-11-24Clinical Trial Update: Study on Therapy of Non-invasive Prolactinoma [NA]
A clinical trial is studying therapy for non-invasive prolactinoma at Sun Yat-Sen University, with unknown status.
-
CLINICAL_TRIALS research · 2017-05-16Clinical Trial Update: Dopamine Agonists Withdrawal Study of Invasive Prolactinomas Involving the Cavernous Sinus
Clinical trial update on a study investigating withdrawal of dopamine agonists in patients with invasive prolactinomas involving the caverno…
-
CLINICAL_TRIALS research · 2015-07-31Clinical Trial Update: Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools [NA]
A clinical trial update from Unity Health Toronto assessing patient education tools for pituitary disorders; no phase or results information…
-
FDA approval · 2014-11-26FDA Approved: BROMOCRIPTINE MESYLATE — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved a supplemental application for bromocriptine mesylate submitted by ANI Pharmaceuticals, Inc. This action updates the regula…
-
CLINICAL_TRIALS research · 2011-11-01Clinical Trial Update: Turmeric Effect on Reduction of Serum Prolactin and Related Hormonal Change and Adenoma Size in Prolactinoma Patients [Phase 1]
Phase 1 clinical trial evaluating turmeric's effect on serum prolactin levels and adenoma size in prolactinoma patients.
-
FDA approval · 2011-10-26FDA Approved: CABERGOLINE — Supplemental Application (SOLA Pharmaceuticals, LLC)
FDA approved SOLA Pharmaceuticals’ supplemental application for cabergoline (generic), granting approval for commercialization of the generi…
-
FDA approval · 2011-10-26FDA Approved: CABERGOLINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for cabergoline submitted by Teva Pharmaceuticals USA, Inc.
-
FDA approval · 2011-08-11FDA Approved: CABERGOLINE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for cabergoline from Mylan Pharmaceuticals Inc., updating the product's labeling.
-
CLINICAL_TRIALS research · 2010-06-14Clinical Trial Update: Efficacy of Rapid Escalation of Cabergoline in Comparison to Conventional Dosing in Prolactin Secreting Macroadenomas. [NA]
This clinical trial update evaluates rapid escalation of cabergoline dosing versus conventional dosing for prolactin-secreting macroadenomas…
-
CLINICAL_TRIALS trial_result · 2008-06-16Clinical Trial Update: Clomiphene in Males With Prolactinomas and Persistent Hypogonadism [Phase 2]
A Phase 2 trial evaluating clomiphene in men with prolactinomas and persistent hypogonadism has completed.
-
FDA approval · 2008-06-04FDA Approved: CABERGOLINE — Supplemental Application (SOLA Pharmaceuticals, LLC)
FDA approved a supplemental application for cabergoline submitted by SOLA Pharmaceuticals, LLC.